Table IV.
Studies of preoperative NAC and NACRT for rectal cancer.
| A, NAC | ||||||
|---|---|---|---|---|---|---|
| Author, year | n | Regimen of chemotherapy | Courses | Radiation | pCR rate (%) | (Refs.) |
| Ishii et al, 2010 | 26 | 5-FU, LV, Irinotecan | 2 | None | 3.8 | (12) |
| Hasegawa et al, 2014 | 25 | XELOX, Bevacizumab | 4 | None | 4 | (13) |
| Schrag et al, 2014 | 32 | FOLFOX, Bevacizumab | 6 | None | 25 | (14) |
| Kamiya et al, 2016 | 41 | XELOX | 4 | None | 12.2 | (15) |
| Hasegawa et al, 2017 | 60 | mFOLFOX6 | 6 | None | 16.7 | (16) |
| B, NACRT | ||||||
| Author, year | n | Regimen of chemotherapy | Courses | Radiation | pCR rate (%) | (Refs.) |
| Rödel et al, 2003 | 32 | XELOX | 2 | 50.4 Gy | 19.0 | (17) |
| Bosset et al, 2005 | 473 | 5-FU, LV | 5 | 45 Gy | 13.7 | (10) |
| Tulchinsky et al, 2008 | 132 | 5-FU | 5 | 45-50.4 Gy | 28.0 | (18) |
| Roh et al, 2009 | 1,113 | 5-FU, LV | 7 | 45 Gy | 15.0 | (19) |
Where the n number represents the number of patients who underwent surgery following NAC or NACRT, and their pCR rate was evaluated in the presented studies. NAC, neoadjuvant chemotherapy; NACRT, neoadjuvant chemoradiotherapy; pCR, pathological complete response; 5-FU, Fluorouracil; LV, leucovorin; XELOX, oxaliplatin and capecitabine; FOLFOX, folinic acid, fluorouracil and oxaliplatin.